Skip to content

Evaluation of efficacy and safety of microwave in reducing lower face laxity

Evaluation of efficacy and safety of microwave in reducing lower face laxity

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250323002
Enrollment
30
Registered
2025-03-23
Start date
2024-10-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient with lower face laxity lower face laxity, microwave

Interventions

Patient were treated with microwave at lower face 3 session spaced 2 weeks apart. The patient was follow at 1, 3, 6, 9 and 12 months after treatment.
Experimental Device

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. age 18 to 60 years old 2. asian descend with Fitzpatrick Skin type III-V 3. mild to moderate degree of lower face laxity 4. consent to receive treatment and follow up

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant, lactating, and postpartum within 1 year 2. Patients who have metallic implant at face, oral braces and metallic implant at face 3. Patients with other skin diseases, or having infection at the area of face 4. Immunocompromised patients 5. Patients with cancers or skin cancers 6. Patients with mental disorders 7. Patients who have oral contraceptive pill, isoretinoin medication with in 6 months before study 8. Patient who have history of laser within 3 months 9. Patients who have been injected with platelet rich plasma polycaprolactone, hyaluronic acid, polydioxanone, poly-L-lactic or calcium hydroxyapatite with in 12 months

Design outcomes

Primary

MeasureTime frame
volume change baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment Quantificare

Secondary

MeasureTime frame
wrinkle baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatmen antera,texture baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatmen antera,Lifting vector baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment Quantificare,skin elasticity baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment Cutometer,melanin baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment mexameter,erythema baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment mexameter,hydration baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment corneometer,patient improvement scale baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment GAIS,adverse event baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1-,3-,6-,9-,12- months after complete treatment note,pain score baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment visual analog score

Countries

Thailand

Contacts

Public ContactWoraphong Manuskiatti

Faculty of Medicine Siriraj Hospital, Mahidol University

woraphong.man@mahidol.ac.th0819150555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026